换一批
换一批摘要Afatinib, an oral tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER-2) and HER4, has been approved in treating patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Additionally, it also has efifcacy in other tumors. Currently, the recommended dose of afatinib is 40 mg once daily, but in clinical trials, the other doses are also used. This article mainly summarized the usage of afatinib alone or combined with other drugs in clinical trials, hoping to provide a better treatment reference for its clinical application.
更多相关知识
DOI
10.11910/2227-6394.2016.04.02.03
发布时间
2016-07-15
- 浏览12
- 被引0
- 下载0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
